CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Comparison of Outcomes of Percutaneous Coronary Intervention on Native Coronary Arteries Versus on Saphenous Venous Aorta Coronary Conduits in Patients With Low Left Ventricular Ejection Fraction and Impella Device Implantation Achieved or Attempted (from the PROTECT II Randomized Trial and the cVAD Registry) A Controlled Trial of Rivaroxaban After Transcatheter Aortic-Valve Replacement Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double-blinded, placebo-controlled randomized trial Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular DiseaseA Prespecified Analysis From the FOURIER Trial Revascularization in Patients With Left Main Coronary Artery Disease and Left Ventricular Dysfunction Long-Term Outcomes After PCI or CABG for Left Main Coronary Artery Disease According to Lesion Location Right ventricular function and outcome in patients undergoing transcatheter aortic valve replacement Ticagrelor versus clopidogrel in patients with acute coronary syndromes Transcatheter Versus Surgical Aortic Valve Replacement in Low-Risk Patients

Original Research2022 Jun 20;e13826.

JOURNAL:Eur J Clin Invest. Article Link

Prognostic implication of lipidomics in patients with coronary total occlusion undergoing PCI

Y Zhou, XD Wang, JY Qian et al. Keywords: biomarker; CTO; CAD; lipidomics; risk prediction

ABSTRACT

BACKGROUND - Predictors of prognosis in patients with coronary chronic total occlusion (CTO) undergoing elective percutaneous coronary intervention (PCI) have remained lacking. Lipidomic profiling enable researchers to associated lipid species with disease progression and may improve the prediction of cardiovascular events.


METHODS In the present study, 781 lipids were measured by targeted lipidomic profiling in 350 individuals (50 healthy controls, 50 patients with coronary artery disease and 250 patients with CTO). L1-regularized logistic regression was used to identify lipid species associated with adverse cardiovascular events and create predicting models which were verified by 10-fold cross-validation (200 repeats). Comparisons were made between a traditional model constructed with clinical characteristics alone and a combined model built with both lipidomic data and traditional factors.


RESULTS 24 lipid species were dysregulated exclusively in patients with CTO, most of which belonged to sphingomyelin (SM) and triacylglycerol (TAG). Compared with traditional risk factors, new model combining lipids and traditional factors had significantly improved performance in predicting adverse cardiovascular events in CTO patients after PCI (area under the curve, 0.870 vs. 0.726, p < 0.05; Akaike information criterion, 129 vs. 156; net reclassification improvement, 0.312, p < 0.001; integrated discrimination improvement, 0.244, p < 0.001). Nomogram was built based on the incorporated model and prove efficient by Kaplan-Meier method.


CONCLUSIONS - Lipidomic profiling revealed lipid species which may participated in the formation of CTO and could contribute to the risk stratification in CTO patients undergoing PCI.